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Ras inhibitionThe importance of the oncogene Ras in cardiac hypertrophy iswell appreciated. The hypertrophic effects of the con-
stitutively active mutant Ras-Val12 are revealed by clinical syndromes due to the Ras mutations and experimental
studies. We examined the possible anti-hypertrophic effect of Ras inhibition in vitro using rat neonatal
cardiomyocytes (NRCM) and in vivo in the setting of pressure-overload left ventricular (LV) hypertrophy (POH)
in rats. Ras functionsweremodulated via adenovirus directed gene transfer of activemutant Ras-Val12 or dominant
negativemutant N17-DN-Ras (DN-Ras). Ras-Val12 expression in vitro activates NFAT resulting in pro-hypertrophic
and cardio-toxic effects on NRCM beating and Z-line organization. In contrast, the DN-Ras was antihypertrophic on
NRCM, inhibited NFAT and exerted cardio-protective effects attested by preserved NRCM beating and Z line struc-
ture. Additional experiments with silencing H-Ras gene strategy corroborated the antihypertrophic effects of
siRNA-H-Ras on NRCM. In vivo, with the POH model, both Ras mutants were associated with similar hypertrophy
twoweeks after simultaneous induction of POH and Ras-mutant gene transfer. However, LV diameters were higher
and LV fractional shortening lower in the Ras-Val12 group compared to control and DN-Ras. Moreover, DN-Ras re-
duced the cross-sectional area of cardiomyocytes in vivo, and decreased the expression ofmarkers of pathologic car-
diac hypertrophy. In isolated adult cardiomyocytes after 2 weeks of POH and Ras-mutant gene transfer, DN-Ras
improved sarcomere shortening and calcium transients compared to Ras-Val12. Overall, DN-Ras promotes a more
physiological formof hypertrophy, suggesting an interesting therapeutic target for pathological cardiac hypertrophy.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Small GTP binding-proteins are a superfamily of proteins acting as
molecular switches between extracellular signals and molecular, diacylglycerol; IP3, inositol
hatidyl,inositol 3,kinase; AKT,
ta; CaN, calcineurine, protein
MEKK, mitogen, activated pro-
ial Avanzada, Avenida Fray Luis
uri).pathways [1,2]. The Ras subfamily is the most important of the GTPases
and includes three main homologous variants: H-Ras, K-Ras and N-Ras.
The 3 genes are expressed ubiquitously with some variation in patterns
of expression and function in developing and adult tissues [3,4].
H-Ras hyperactivity in the cardiomyocyte is associated with hyper-
trophy [2,5]: i) In Costello's syndrome, patients with activating muta-
tions of Ras develop hypertrophic cardiomyopathy with atrial
tachycardia [6]. ii) Transgenic mice expressing the constitutively active
mutant Ras-Val12 demonstrate ventricular hypertrophy similar to
human hypertrophic cardiomyopathy [7]. iii) Mouse models of induc-
ible cardiac overexpression of Ras-Val-12 have shown pathological fea-
tures of cardiac hypertrophy [8]. Hypertrophy, deranged myoﬁbril
structure and impaired calcium transients are demonstrated in NRCM
treated with Ras-Val-12 [9].
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are associated with cardiac hypotrophy or anti-hypertrophic effects:
i) K-Ras knock-out mice embryos die by day 15.5 of development,
with very thinwalls of cardiac ventricles as the likely cause of embryon-
ic death [3]. ii) Thorburn et al. [10] showed that Ras-Ala15 (a negative
interferent mutant of Ras) inhibits NRCM hypertrophy activated by
phenylephrine (PE). Fuller et al. showed that N17-DNRas (DN-Ras) in-
hibits the hypertrophic effect of the active mutant of Src-Phe527 [11].
iii) Pracyk et al. [12] demonstrated the anti-hypertrophic effect of the
DN-Ras in neonatal cardiomyocytes at baseline, but not under stimula-
tion by endotheline 1. iv) Recently, Nagalingam et al. [13] demonstrated
the in vitro anti-hypertrophic effect of miR-378, a MicroRNA that nega-
tively regulates Ras signaling in cardiac hypertrophy.
However, the study of the effects of Ras on cardiac hypertrophy is
made difﬁcult by the complex and poorly understood regulatory bal-
ance between proteins of the Ras superfamily; moreover, there are sev-
eral examples of paradoxical responses to Ras-dependent stimuli, such
as Ras and Rap1 divergent actions [1,14].
Rasmutants exert different actions at baseline or under ligand stim-
ulation [12]. Duquesnes et al. [15] have shown that the ERK signaling
pathway was down-regulated by DN-Ras in basal conditions but not
undermechanical stimulation and Harris IS et al. [16] demonstrated ap-
parently paradoxical actions of the Raf1-MAPkinase cascade. Inmice ex-
pressing Ras-Val12 in the ventricles, the phenotype was variable and
heterogeneous [5,7,17].
In this study, we hypothesized that the DN-Ras mutant N17 exerted
an anti-hypertrophic effect in vivo, but we found a mixed agonist–an-
tagonist action on the Ras pathway leading to cardiomyocyte hypertro-
phy or anti-hypertrophic effects, and the balance between the agonist
and antagonist effects of DN-Ras was stimulus-dependent. Further-
more, and beyond the hypertrophic response, we investigated the im-
pact of DN-Ras and active Ras-Val12 mutants on the pathologic
character of cardiomyocyte hypertrophy. To that end, studies were con-
ducted in vitro with and without pro-hypertrophic ligands, and in vivo
in the setting of pressure-overload left ventricular (LV) hypertrophy
(POH). To corroborate the results obtained by overexpressing dominant
negative and active Ras mutants, a set of experiments was performed
using siRNA-H-Ras on NRCM.
2. Materials and methods
2.1. Recombinant adenovirus vectors
All recombinant adenoviruseswere constructed using a cytomegalo-
virus (CMV) promoter. Cells were infectedwith adenovirus at 50 to 100
MOI (multiplicities of infection) per cell. We used recombinant
adenoviral vectors encoding two variants of the H-Ras gene: the domi-
nant negative mutant S17N (Ad-DNRas) and the oncogenic active
mutant G12V (Ad-Val12). TheDN-Rasmutant of Ras (substitution of as-
paragine for serine at the 17th amino-acid) is locked in its inactive form
(Ras-GDP), due to a reduced afﬁnity for GTP and preserved afﬁnity for
GDP [18]. The active mutant Ras Val12 (a substitution of glycine for va-
line, G12V, in the 12th amino-acid) was used as a positive control for
DN-Ras [5]. Ad-βGal, encoding β-galactosidase under CMV promoter
followed by target gene-IRES-reporter gene (a green ﬂuorescent protein
(GFP)) construct translated as two independent proteins [19] was used
as an additional control; Ad.NFAT-Luc virus, carrying the luciferase re-
porter gene controlled by NFAT- responsive promoter [20] was used
to measure NFAT activation. Ad-VIVIT, encoding NFAT competing pep-
tide VIVIT and GFP under CMV promoter [21,22] was used as an addi-
tional control for NFAT-reporter experiments.
2.2. Isolation and culture of neonatal rat cardiomyocytes (NRCM)
Spontaneously beating NRCM were isolated from 1 to 2-day-old
Sprague–Dawley rat pups using the Worthington NeonatalCardiomyocyte Isolation System (Worthington Biochemical Corp.) as
previously described [23]. Cardiomyocytes were plated in 12-well
plates for 36 h in serum-free medium then transducedwith the recom-
binant adenoviruses (Ad-DNRas, Ad-Val12, or Ad-βGal) or no virus as
control group.
For experiments using siRNA-H-Ras, NRCM were plated in 6-well
plates in triplicates and transfected with 50 nM Hras-siRNA (Santa
Cruz Biotechnology) with RNAiMAX Transfection Reagent (Invitrogen)
for 24 h. Control cells were treated with only RNAiMAX Transfection
Reagent for 24 h. Scramble siRNA had no effect on NRCM compared to
control in observations published elsewhere [24] where scramble
siRNA does not affect calcium transient and contractility in NRCM com-
pared to control.
Cells were then serum starved for 30 h before they were stimulated
with phenylephrine (PE) (1 μM) for an additional 24 h. Cells were then
harvested and homogenized for RNA and proteins preparation.
2.3. Protein synthesis assay
Protein synthesis ratewasmeasuredusing the [3H]-Leucine incorpo-
ration assay as previously described [23]. Brieﬂy, NRCM were trans-
duced with the relevant adenovirus for 48 h. Then, NRCM were
stimulated for 7 h with PE (1 μM) or angiotensin-II (1 μM) in the pres-
ence of [3H]-Leucine. Protein synthesis was quantiﬁed by [3H]-Leucine
incorporation measured by scintillation counting (MicroBeta Trilux,
Perkin Elmer).
2.4. In vitro and in vivo cardiomyocyte size measurement
Cell surface areas were measured on micrographs using the ImageJ
software (NIH). At least 50 individual cellswere analyzed for each exper-
imental condition. For in vivo experiments, the size of cardiomyocytes
was evaluated on cross sections using Wheat germ agglutinin (WGA)
Alexa Fluor® 488 conjugate (Invitrogen).
2.5. In vitro beating analysis
Wedesigned a protocol to keep NRCMbeating for prolonged periods
of time, and analyzed the inﬂuence of experimental genes on beating.
NRCM were maintained with 2% serum in the medium instead of
serum-free (0.1% serum)medium. After 24 hwith 2% serum, gene trans-
ferwas performed. Subsequent dailymeasurement of beating frequency
was performed during 2 weeks. The beating frequency (beat/min) was
counted in three different points of thewell. The in vitro beating analysis
was repeated three times, and with two wells per group each time.
2.6. Immunoﬂuorescence
The sarcomeric structure of NRCMwas analyzed by immunoﬂuores-
cence with anti alpha-actinin (Sigma A2543), using standard protocol.
Secondary antibody was a-rabbit IgG conjugated with Alexa 555
(Invitrogen). Slides were analyzed by confocal microscopy (Leica TCS-
SP confocal microscopy).
2.7. Quantitative Real time PCR
Total RNAwas isolated with TRIzol reagent (Invitrogen). Expression
of H-Ras, beta-Myosin-heavy-Chain (β-MHC), atrial natriuretic factor
(ANF) and B-type natriuretic peptide (BNP) mRNA in NRCM and LV tis-
suewas quantiﬁed using real timeRT-PCR (RT-PCR) analysis (7500 real-
time PCR system, Applied Biosystems) performed according to standard
procedures. Quantiﬁcation of relative expression used thedelta-delta-Ct
approach. The following primers were used:
Rat-18S-F: 5′-GTTGGTTTTCGGAACTGAGGC-3′
Rat-18S-R: 5′-GTCGGCATCGTTTATGGTCG-3′
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Rat-H-Ras-R: 5′-CCGAGACTCAACAGTGCGA-3′
Rat ANF-F: 5′-ACC TGC TAG ACC ACC TGG AGG AG-3′
Rat ANF-R: 5′-CCT TGG CTG TTA TCT TCG GTA CCG-3′
Rat β-MHC-F: 5′-TTG GCA CGG ACT GCG TCA TC-3′
Rat β-MHC-R: 5′-GAG CCT CCA GAG TTT GCT GAA GGA-3′
Rat BNP-F: 5′-GCT GCT TTG GGC ACA AGA TAG-3′
Rat BNP-R: 5′-GGT CTT CCT ACA ACA ACT TCA-3′.
2.8. Immunoblot analysis
Protein sampleswere prepared using a lysis buffer containing prote-
ase and phosphatase inhibitors (Roche), separated by SDS-PAGE and
transferred on nitrocellulose membranes (Millipore). The membranes
were blotted using standard protocol and revealed by chemilumines-
cence (Pierce). The following antibodies were used: p44/42MAP kinase
(Thr202/Tyr204) (Catalog No. 9101, Cell Signal Technology); p44/42
MAP kinase (Catalog No. 9102, Cell Signal Technology); Anti H-Ras
proto-oncogene (Catalog No. SC-520 Santa Cruz Biotechnology), anti-
pERK1/2, and anti-ERK1/2 (ref), Phospho-c-Raf (ser-259) (Catalog No.
9421 Cell Signaling Technology); Anti-Raf (CatalogNo. 9422 Cell Signal-
ing Technology) and anti-GAPDH: (Catalog No. 2118; Cell Signaling
Technology). The densities of the immune-reactive bands were quanti-
ﬁed using ImageJ software (NIH).2.9. NFAT-promoter-Luciferase Reporter Assay
NRCM were infected with Ad.NFAT-LUC virus [20], 48 h after
prior infection with Ras mutants and control adenoviruses. Ad-
VIVIT and FCS (10%) were used as negative and positive controls,
respectively, for NFAT-reporter experiments. Luciferase activity
was measured using the Luciferase Assay System (Promega) ac-
cording to the manufacturer's instructions. Luciferase activity was
normalized to total protein concentration for each sample as deter-
mined by Coomassie Protein Assay Reagent (Pierce), and results
were expressed as relative luciferase units per microgram of pro-
tein (RLU/μg).2.10. In vivo adenoviral gene transfer in a rat pressure overload LV
hypertrophy (POH) model
Animal care and procedures were performed with the approval of in-
stitutional animal care committees in accordance with the National Insti-
tute of Health's guide for the Care and Use of Laboratory Animals. Brieﬂy,
male rats (Sprague–Dawley, 250–300 g)were anesthetizedwith an intra-
peritoneal injection of a combination of Ketamine (50–100 mg/kg) and
Xylazine (10 mg/kg). The animal was intubated and ventilated. Midline
thoracotomywasperformedand theheart exposed. Cardiac genedelivery
was performedwith adenoviral vectors as previously reported [25–27]. A
24-gauge Angiocath was advanced from the apex of the LV to the aortic
root. The aorta and pulmonary arteries were cross-clamped simulta-
neously distal to the site of the catheter, injecting the solution of adenovi-
rus or control (saline solution), containing approximately 1010 plaque-
forming units of the viruses, mixed with adenosine (50 μl of a solution
of adenosine 2 mg/ml). The cross-clamp was maintained for 30 s. The
blanching of the heart during the cross clamping indicated effective
intracoronary injection. After the adenovirus delivery, ratswere subjected
to ascending aortic bandingwith a 0.58mm(internal diameter) tantalum
clip as previously described [25,26]. A groupof rats underwent a shamop-
eration. The chest was vacuumed for removal of air and blood and closed
in 3 layers. Four groups of animals were therefore studied a) Sham oper-
ated rats, b)POHwith saline injection, c) POHwithAd.DN-Ras gene trans-
fer, and d) POH with Ad.RasV12 gene transfer.2.11. Echocardiography and morphometric analysis
In vivo LV size and function was assessed by echocardiography at
baseline (before surgery) and two weeks after surgery (prior to animal
sacriﬁce). Animals were sedated with an intra-peritoneal injection of
ketamine (50 mg/kg). Transthoracic two-dimensional (2D) and M-
mode echocardiography was performed with a General Electric Vivid
7 system (General Electric, New York, NY) using an i13L 14 MHz trans-
ducer. M-mode echocardiography was performed on a mid-papillary-
level LV short axis view as previously described [28]. After terminal
echocardiography, rats were sacriﬁced and their hearts harvested. LV
and right ventricle were separated and weighed. A ring of tissue from
the LV mid-cavity was embedded for histological analysis. The rest of
the LV tissue was frozen for protein and RNA analysis. Selected hearts
were used for cardiomyocyte isolation (see next paragraph).
2.12. Adult rat cardiomyocyte contractility and calcium transient
assessment
Ventricular myocytes were isolated from rats two weeks after aortic
constriction surgery and ras-mutant gene transfer via enzymatic disso-
ciation, as previously described [29].
Cardiomyocytes were ﬁeld-stimulated at a frequency of 1 Hz and
were studied using the IonOptix system, as previously described [29].
Sarcomeric shortening and relaxation were assessed using a video-
based edge detection system (IonOptix). Calcium transients were ob-
tained by loading cells with 0.5 μM fura2-AM (Invitrogen) and record-
ing ﬂuorescence measurements with a dual-excitation single-emission
ﬂuorescence photomultiplier system (IonOptix), as previously de-
scribed [29].
2.13. Statistical analysis
Statistical analysis used Student's T test or corresponding non-
parametric tests; statistical signiﬁcance threshold was p b 0.05. All
quantitative data are presented as mean ± standard error of the mean
or standard deviation (SEM or SD).
3. Results
3.1. Role of Ras in hypertrophic remodeling: a mixed agonist–antagonist ef-
fect of DN-Ras
Wehave examined the role of Ras in the hypertrophy-related signal-
ing pathway using the neonatal rat cardiomyocytes (NRCM) and adeno-
virus encoding either constitutively active H-Ras (Ad-Val12) or
dominant negative (Ad-DNRas). The expression of Ras mutants in
NRCM was demonstrated by immunoblot analysis (Fig. 1A). As shown
in Fig. 1A, transducing NRCM with a different range of MOI (10 to 500
MOI per cell) resulted in similar expression increase of Ras protein
(Fig. 1A).
Next, we analyzed the effect of different Ras mutants on hypertrophic
growth of NRCM at baseline or with stimulation by PE (Fig. 1B). At base-
line, a signiﬁcant increase of cardiomyocyte area was observed only in
NRCM transduced with Ad-Val12 (Fig. 1B). As expected, PE treatment
(1 μM, 48 h) resulted in a signiﬁcant increase of cardiomyocytes size in
non-infected or Ad-βGal transduced NRCM (Fig. 1B). However in Ad-
Val12-transduced group, PE treatment did not produce any additional ef-
fect on cell size, suggesting that Ras-Val12 activity was sufﬁcient to
achieve themaximal hypertrophic response. Although DN-Ras had no ef-
fect on cardiomyocyte size at baseline, it signiﬁcantly inhibited PE-
induced (1 μM, 48 h) hypertrophic growth of cardiomyocytes (Fig. 1B).
Since NRCM hypertrophy is associated with an increase in protein
synthesis [30], we assessed the effect of Ras mutants on Leucine incorpo-
ration (Fig. 1C). As expected, Angiotensin-II (AT-II) and phenylephrine
(PE) both increased Leucine incorporation compared with untreated
Fig. 1.Modulation of hypertrophic remodeling of NCRM by Rasmutants. A. Expression of Ras proteins in transduced NRCM. Representative immunoblot showing expression of H-Ras pro-
tein inNRCM transduced for 48 hwith relevant adenoviruses atmultiple ranges ofMOI (Multiplicity of Infection). Expression of H-Raswas low to undetectable in non-transduced or β-gal
transducedNRCMat this time of exposure. B.Modulation of cell size byRas-mutants and Phenylephrine (PE) inNRCM. Relative cardiomyocyte size (cell area) of control or transducedwith
indicated adenovirus NRCM. Cells were cultured for 48 h with PE (1 μM) or vehicle. Area values were normalized to area of control (nontransduced) NRCM. Number of cardiomyocytes
measured for each condition was ~60 from three independent experiments. ***p b 0.001. C. Modulation of protein synthesis ([3H]-Leucine incorporation) by Angiotensin-II (AT-II), Phen-
ylephrine (PE) and Ras-mutants inNRCM. Bar-graph showing [3H]-Leucine byNRCMunder different conditions. NRCMwere transducedwith Ad-βGal, Ad-DNRas or Ad-RasVal12 for 48 h,
and stimulated for 7 h with Phenylephrine (PE) (1 μM) or Angiotensin-II (1 μM) in the presence of [3H]-Leucine. The data are presented as normalized mean ± standard error (SEM) of
three independent experiments performed in triplicate. *p b 0.05; ***p b 0.001. D. Ras controls themajor prohypertrophic transcription factor NFAT. Promoter-reporter assay of NFAT tran-
scriptional activity. Twenty-four hours after transduction with Ad-NFAT-Luc, NRCMwere infected with indicated Ad-βGal, Ad-Val12, Ad-DNRas or Ad-VIVIT for 48 h. Ad-VIVIT, encoding
NFAT competing peptide VIVIT and GFP under CMV promoter and FCS (10%) were used as negative and positive controls, respectively. Data (mean values ± SEM of at least three inde-
pendent experiments) are expressed in relative luciferase units (RLU) as a percentage of value in Ad-βGal infected cells. *p b 0.05; ***p b 0.001.
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icant effect on Leucine incorporation at baseline, while it prevented the
increase in protein synthesis when cells were stimulated with AT-II
or PE, in contrast with all other groups. As expected, Ras-Val12 in-
creased Leucine incorporation at baseline, and further increased it
in stimulated states (Fig. 1C).
Then, in order to determine if Ras is involved in the control of
hypertrophy-related signaling pathways, we analyzed the effect of
different Ras proteins on the transcriptional activity of NFAT, the
main activator of pathological cardiomyocyte hypertrophy [31]. As
demonstrated in Fig. 1D, NFAT-luciferase activity was increased in
cardiomyocytes cultured in the presence of FCS (10%) and complete-
ly abolished in cardiomyocytes expressing the NFAT-competing
peptide VIVIT, even in the presence of ATII, attesting to the speciﬁcity
of the effect observed (Fig. 1D). The transduction with control
adenovirus (Ad-βGal) had no signiﬁcant effect on basal NFAT-
luciferase activity (Fig. 1D), while the expression of Ras-Val12 was
sufﬁcient to induce a robust increase of NFAT transcriptional activity,
even in the absence of other stimuli (Fig. 1D), conﬁrming previous
observations [32]. As expected, ATII, which is known to induce
an increase in intracellular Ca2+[33], thereby activating the
Ca2+-dependent cytosolic factor NFAT [34] signiﬁcantly increased
NFAT-luciferase activity in Ad-βGal transduced cells, but could not in-
crease this activity further in AdVal12 transduced cardiomyocytes,
suggesting that RasVal12 maximally activated NFAT at the basalstate (Fig. 1D). Remarkably, DNRas has no effect on basal NFAT-
luciferase activity but prevents the increase in this activity in the
presence of ATII (Fig. 1D), in agreement with its effect on protein syn-
thesis (Fig. 1C).3.2. Activation of Ras adversely affects NRCM
Because hypertrophic remodeling is associated with alteration of
cardiomyocyte structure and contractility, more precisely reduced sar-
comere shortening and impaired contraction [35], we examined the ef-
fect of Ras mutants on spontaneous beating and sarcomere structure of
NRCM (Fig. 2). NRCM were transduced with either Ad-Val12 or Ad-
DNRas or Ad-βGal (control); spontaneously beating cells were moni-
tored in culture for 14 days. In control cells (transduced with Ad-
βGal), the rate of spontaneously beating cells was high (60 beats/min)
until Day 5 after transduction. Then, the beating rate decreased dramat-
ically to total cell beating arrest at Day 9. In the cells transduced with
Ad-Val12, the beat rate dramatically decreased shortly after transduc-
tion to near arrest at Day 3 and was signiﬁcantly lower than controls
(Fig. 2A). By contrast, in the cultures transduced with Ad-DNRas, the
beating rate decreased after transduction (Day 2) but remained stable
in the range of 20 to 40 beats/min until the end of experiment (Day
14). Thus, DN-Ras preserved NRCM beating, while Ras-Val12 abolished
it, compared to control.
Fig. 2. Activation of Ras leads to sarcomeric disorganization and impaired beating in NRCM. A. Monitoring of spontaneous beating frequency in NRCM transduced with Ad-βGal, Ad-Ras-
Val12 or Ad-DNRas during 14 days. Cells were transduced at Day 0. n = 4 cells per time point and per condition. Both Ras-Val12 and DN-Ras were compared to Beta-Gal with *p b 0.05,
**p b 0.01 and ***p b 0.001 and DN-Ras was compared to Ras-Val12 with $p b 0.05, $$p b 0.01 and $$$p b 0.001 B, C and D. Analysis of sarcomeric structure of NRCM transduced with Ad-
βGal (B); Ad-Ras-Val12 (C) or Ad-DNRas (D) for 3 days. Left panel: immunoﬂuorescencewithα-Actinin showing the position of the Z-band. Right panel: proﬁle showing the optical den-
sity (gray plot) along the white line. Images show the representative pattern observed in at least 60% of the cells. Magniﬁcation 40×.
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disorganization, we analyzed the effect of Ras mutants on α-actinin
accumulation in Z-lines. It is known that i) α-actinin cross-links sarco-
meric actin to Z-disk proteins; and ii) accumulation of α-actinin in theZ-disk depends on its phosphorylation [36] and iii) Ras-Val12 impairs
sarcomeric structure [9].
Immunoﬂuorescence with anti-α-actinin revealed a strong sarco-
meric organization in control non-infected (not shown) or Ad-βGal
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decreasedα-actinin accumulation in Z-disks suggesting disorganization
of sarcomere structure (Fig. 2B). Interestingly, when NRCM were
transducedwith DN-Ras, theα-actinin accumulation to Z-disk was pre-
served (Fig. 2B), suggesting normal sarcomeric organization. Thus, ex-
pression of constitutive active Ras (Ras-Val12) resulted in impaired
cardiomyocyte beating supported by loss of α-actinin accumulation in
Z-disk leading to sarcomeric disorganization.
3.3. Differentialmodulation of ERK and RAF phosphorylation by Rasmutants
The mechanism of action of DN-Ras was analyzed in the Ras-related
pathway, speciﬁcally ERK phosphorylation modulation by Ras mutants
when the NRCM were stimulated with AT-II or PE (1 μM, 10 min)
(Fig. 3). Both AT-II and PE signiﬁcantly increased ERK phosphorylation
in NRCM (Fig. 3A&B). As expected, Ras-Val12 greatly increased ERK
phosphorylation in the basal state and this activation is maintained
under either stimulus (PE or AT-II) (Fig. 3A). By contrast, at basal state
DN-Ras did not affect ERK phosphorylation (Fig. 3B). Moreover, DN-
Ras expression prevented the increase of ERK phosphorylation under
AT-II treatment (Fig. 3B). However, DN-Ras did not prevent ERKFig. 3.Modulation of ERK (A and B) and RAF (C and D) phosphorylation by Ras mutants under
phorylation of ERK and Raf proteins at the basal conditions or under stimulation by AT-II (1 μM
the same proteins. Data (mean values± SEM of at least three independent experiments) are exphosphorylation when activated by PE (Fig. 3B), indicating a stimulus-
dependent antagonist activity of DN-Ras.
We also examined the modulation of RAF phosphorylation under
the same conditions. Indeed, RAF is currently considered as aﬁrst down-
stream signaling molecule in RAS signaling cascade [37]. Surprisingly,
AT-II and PE treatment only mildly increased RAF phosphorylation
in NRCM (Fig. 3C&D). Along with this, Val-12 had a modest effect
on RAF phosphorylation under basal conditions and did not affect
Raf under PE or AT-II stimulation (Fig. 3C). Regarding the effect of DN-
Ras on RAF, it mildly reduces RAF under AT-II and PE stimulation
(Fig. 3D).
In summary, our in vitro data show that the expression of constitu-
tive active Rasmutant is sufﬁcient for induction of hypertrophic remod-
eling through NFAT activation. Dominant negative Ras has no effect on
transcriptional activation of NFAT, but exert amixed agonist–antagonist
effect depending on the concurring hypertrophic stimulus.
3.4. Effect of siRNA-HRas on NRCM hypertrophy
Since the experiments involving dominant negative or activating
Ras mutants required the over-expression of the mutant, and inAT-II or PE stimulation. Upper panel: typical immunoblot showing relative levels of phos-
, 10 min) or PE (1 μM, 10min). Lower panel: bar-graph showing the relative expression of
pressed as a percentage of value in control condition (non infected, non treated). *p b 0.05.
Fig. 4. Impact of siRNA-H-Ras treatment on phenylephrine-induced hypertrophy in NRCM. A. Normalized expression of the H-Ras mRNA; N = 3 per condition, t-test performed on the
delta-delta-Ct. B. NRCM size after treatment with siRNA-H-Ras and/or PE. N = 84 to 122 cells per conditions were measured. C, D and E. Normalized expression of the mRNA of βMHC,
ANF and BNP;N=2–3 per condition, t-test performed on the delta-delta-Ct. F.Western blot and band quantiﬁcation of the phosphorylation of ERK1 and ERK2; N=2bands per condition.
*p b 0.05, **p b 0.01 and ***p b 0.001.
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independence of the hypertrophic phenotype under study, we
sought to corroborate our results with those of a silencing strategy
using siRNA-HRas (Fig. 4). The successful knockdown of H-Ras
mRNA in NRCM under both unstimulated and PE-stimulated condi-
tions by siRNA-HRas treatment was attested by the quantitative
real time RT-PCR analysis (Fig. 4A). Knockdown of H-Ras by siRNA-
HRas did not affect NRCM size at baseline but prevented the increase
in NRCM size induced by PE (Fig. 4B). Interestingly, siRNA-HRas sup-
pressed the baseline expression of themRNA of β-MHC, ANF and BNP
in NRCM (Fig. 4C–D–E). The expression of these 3 genes markedlyincreased under PE stimulation, and this increase was blunted by
the addition of siRNA-HRas (Fig. 4C–D–E). Nevertheless, PE retained
a modest but signiﬁcant stimulatory effect on the expression of β-
MHC and ANF in the presence of siRNA-HRas (Fig. 4C–D–E), suggest-
ing the parallel activity of Ras-dependent and Ras-independent
mechanisms. A similar pattern was observed for the phosphorylation
of ERK1, which was reduced by siRNA-HRas at baseline and stimulated
by PE (Fig. 4F). The phosphorylation of ERK1was still increased by PE in
the presence of siRNA-HRas, however, this increase was blunted
(Fig. 4F). PE and Ras siRNA did not signiﬁcantly affect ERK2 phosphory-
lation (Fig. 4F).
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of multiple neurohormonal responses and intracellular signaling path-
ways involved in the regulation of cardiac myocyte size and function.
Thus, we hypothesized that in vivomodulation of intracellular signaling
by Ras mutants results in differential adaptation of heart function to
pressure overload. Therefore, we have analyzed the effect of Ras mu-
tants on cardiac remodeling in a left ventricle (LV) pressure overload
hypertrophy (POH) model.
3.5. Concurrent effect of Ras mutants and pressure-overload on early cardi-
ac hypertrophy
Pressure-overload hypertrophy (POH) was induced in rats by aortic
banding simultaneously with the gene transfer of Ras mutants. TheFig. 5. Impact of Ras gene transfer on left ventricular pressure-overload hypertrophy. A. Represen
in LV of control animals or animals transduced with indicated virus. n = 2 per group, *p b 0.05
markers (ANF (B) and beta-MHC (C)) in LV tissue from control animals or POH animals transd
N= 2–3 animals per group. *p b 0.05; **p b 0.01 for t-test performed on the delta-delta-Ct. D. A
imals transducedwith indicated adenovirus. Left panel: Germagglutinin staining. Right panel: B
operated animals. 250 individualmeasurements from 5 sectionswere performed for each anim
ison Test).animals were sacriﬁced 2 weeks after surgery. Effective gene transfer
was veriﬁed by the increase in protein expression of Ras (Fig. 5A).
Since there are no speciﬁc antibodies against Ras mutants, increased
total Ras protein (H-Ras) expression indicated effective gene transfer
(Fig. 5A).
3.5.1. DN-Ras prevented the pathologic hypertrophic remodeling of
cardiomyocytes in the setting of POH
mRNA expression of hypertrophy-related genes was analyzed in LV
tissue with POH with and without gene transfer of Ras mutants
(Fig. 5B&C). As expected, POH increased the mRNA of ANF and β-MHC
in LV tissue. Constitutively active Val12Ras further augmented the
expression of hypertrophy-related genes in LV of POH animals
(Fig. 5B&C). By contrast, DN-Ras prevented the increase of expressiontative immunoblot (left panel) and quantiﬁcation (right panel) showingH-Ras expression
. B&C. Box plots of the RT-PCR analysis of the relative mRNA expression of hyperthrophic
uced with indicated virus. All the groups were normalized versus the levels of 18S mRNA.
nalysis of LV cardiomyocyte cross-sectional area in control (sham operated) and POH an-
ar graph representing themean cardiomyocytes cross-sectional area in3 sham- and4 POH-
al. ***p b 0.001 (Non-parametric Kruskal–Wallis test followed by Dunn'sMultiple Compar-
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protective effect. We have measured the cross-sectional area of LV
cardiomyocytes. As expected, POH signiﬁcantly increased the size of
cardiomyocytes in LV tissue (Fig. 5D). Expression of Val12Ras further
enlarged the cardiomyocytes size as well as cardiomyocytes size vari-
ance in the setting of POH. Conversely, in DN-Ras transduced animals,
the size of LV cardiomyocytes was similar to that in sham-operated an-
imals (Fig. 5D), demonstrating the efﬁcacy of inhibition of Ras signaling
pathway by DN-Ras in early cardiac hypertrophy.
3.5.2. Both Ras-Val12 and DN-Ras increase LV/body weight ratio in the
setting of POH
Twoweeks after POH surgery, both Rasmutants appeared to exert a
pro-hypertrophic effect as indicated by the ratio of LV/body weight,
signiﬁcantly higher than the AoB-saline control (Fig. 6A, Table 1). ThisFig. 6.Morphometric and Echocardiographic analysis of rat LV in the setting of combined POH
tails). *p b 0.05; **p b 0.01; ***p b 0.001. A.Morphometric analysis. LVweight/bodyweight is inc
Ras. AoB, ascending aortic banding. B&C. LV anteroseptal (B) and posterior (C) wall thickness w
mutants. D. LV diastolic diameter at 2weeks was reduced by AoBwith saline or DNRas, but faile
signiﬁcantly increased in the Val12-Ras group compared to other POH. F. LV fractional shorten
with Val12-Ras gene transfer compared to other POH.ﬁnding is compatible with a partial agonist effect of DN-Ras on LV hy-
pertrophy per se in the setting of POH. However, it comes with a trend
to a higher LV weight and to a lower body weight in DN-Ras-
transduced POH animals compared to saline control POH (Table 1).
Rasmutants did not signiﬁcantly affect the increase in LVwall thickness
associated with POH (Fig. 6B&C, Table 1).
3.5.3. Ras-Val12 gene transfer increases LV systolic diameter and reduces LV
fractional shortening compared to DN-Ras in the setting of pressure overload
LV diameters and fractional shortening were examined to test the
hypothesis that, at similar levels of hypertrophy, Ras mutants had a dif-
ferent impact on LV function. As expected in a concentric LV hypertro-
phy pattern, LV diastolic diameters were reduced (compared to sham)
in POH rats injected with saline and after DN-Ras gene transfer; this re-
duction was not signiﬁcant after Ras-Val-12 gene transfer (Fig. 6D,and Ras mutant gene transfer. 7–13 animals per group were analyzed (see Table 1 for de-
reased as a result of POH, and further increased by gene transfer of either DN-Ras or Val12-
ere increased signiﬁcantly in all POH groups. No signiﬁcant difference was related to Ras
d to decrease with Ras-Val12. E. LV systolic diameterwas reduced in all POH groups; it was
ing increased in POH as a result of concentric LV hypertrophy; it was signiﬁcantly reduced
Table 1
Echocardiographic andmorphometric analysis of the left ventricle (LV) after pressure overload hypertrophy (POH) and H-Rasmutants gene transfer (a) LV and bodyweight (BW) (b) LV
diastolic wall thickness (c) LV cavity diameter and fractional shortening. SD, standard deviation.
(a) LV and body weight (BW)
Group BW (g) BW (g) LVweight (mg) LVweight/BW (mg/g)
Timepoint Baseline 2 weeks 2 weeks 2 weeks
Sham Mean 289.00 391.23 869.78 2.20
SD 30.39 33.60 84.86 0.25
n 7 13 9 9
AAB + saline Mean 285.00 382.67 1120.50 2.93
SD 29.31 30.74 142.52 0.34
n 3 6 6 6
p vs. Sham 0.85 0.6 0.0009 0.0003
AAB + DN-Ras Mean 274.83 367.10 1221.43 3.27
SD 39.03 32.41 42.06 0.16
n 6 10 7 7
p vs. Sham 0.47 0.098 b0.0001 b0.0001
p vs. AAB + saline 0.71 0.36 0.0999 0.0401
AAB + Ras-Val12 Mean 270.40 336.30 1108.44 3.25
SD 28.70 33.31 151.85 0.25
n 10 10 9 9
p vs. Sham 0.22 0.0008 0.0008 b0.0001
p vs. AAB + saline 0.46 0.015 0.89 0.054
p vs. AAB + DN-Ras 0.80 0.0505 0.0780 0.91
(b) LV diastolic wall thickness
Group LV anteroseptal wall thickness
in diastole (cm)
LV anteroseptal wall thickness
in diastole (cm)
LV posterior wall thickness
in diastole (cm)
LV posterior wall thickness
in diastole (cm)
Timepoint Baseline 2 weeks Baseline 2 weeks
Sham Mean 0.19 0.20 0.20 0.20
SD 0.02 0.02 0.03 0.03
n 13 13 13 13
AAB + saline Mean 0.19 0.26 0.20 0.27
SD 0.01 0.02 0.02 0.02
n 6 7 6 7
p vs. Sham 0.76 b0.0001 0.74 b0.0001
AAB + DN-Ras Mean 0.19 0.27 0.20 0.28
SD 0.02 0.02 0.03 0.02
n 10 10 10 10
p vs. Sham 0.98 b0.0001 0.79 b0.0001
p vs. AAB + Saline 0.76 0.97 0.92 0.446
AAB + Ras-Val12 Mean 0.17 0.25 0.18 0.26
SD 0.01 0.03 0.02 0.03
n 10 10 10 10
p vs. Sham 0.033 0.0004 0.086 0.0001
p vs. AAB + Saline 0.0046 0.19 0.031 0.306
p vs. AAB + DN-Ras 0.028 0.12 0.039 0.10













Timepoint Baseline 2 weeks Baseline 2 weeks Baseline 2 weeks
Sham Mean 0.58 0.66 0.20 0.24 67 64
SD 0.06 0.07 0.07 0.07 10 7
n 13 13 13 13 13 13
AAB + saline Mean 0.61 0.55 0.21 0.10 65 81
SD 0.05 0.09 0.05 0.02 5 3
n 6 7 6 7 6 7
p vs. Sham 0.28 0.008 0.71 0.0001 0.79 b0.0001
AAB + DN-Ras Mean 0.58 0.60 0.18 0.12 69 81
SD 0.05 0.06 0.06 0.03 8 5
n 10 10 10 10 10 10
p vs. Sham 0.93 0.041 0.46 b0.0001 0.50 b0.0001
p vs. AAB + saline 0.25 0.19 0.24 0.29 0.33 0.89
AAB + Ras-Val12 Mean 0.59 0.62 0.19 0.15 68 76
SD 0.07 0.05 0.06 0.03 7 4
n 10 10 10 10 10 10
p vs. Sham 0.64 0.12 0.87 0.0013 0.76 0.003
p vs. AAB + saline 0.62 0.06 0.55 0.0018 0.48 0.0146
p vs. AAB + DN-Ras 0.69 0.44 0.52 0.013 0.65 0.02
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groups, however, LV systolic diameters were signiﬁcantly higher with
Ras-Val12 gene transfer than with either saline or DN-Ras (Fig. 6E,Table 1). Similarly, concentric POH resulted in an increase in LV fraction-
al shortening; however, fractional shortening was lower in Ras-Val12
compared to DN-Ras and saline (Fig. 6F, Table 1). Altogether, these
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and a possible cardioprotective effect of DN-Ras consistent with what
we observed in NRCM.
3.5.4. Ras-Val12 gene transfer alters cardiomyocytes contractility and
calcium transients compared to DN-Ras in the setting of pressure overload
Ourﬁndings in Fig. 2 further demonstrate a known cardiotoxic effect
of Ras-Val-12 on NRCM, in agreement with previous reports [9], and
suggest a cardioprotective effect of DNRas. Moreover, both Ras mutants
differentially affect contractile function and cardiac hypertrophy in POHFig. 7. Effects of Ras mutants on adult rat cardiomyocyte contractility and Ca2+ transients in the
and myocytes subjected to 2 weeks of POH and simultaneously transduced with Ad.Val12 or A
traction (t1/2 on (s) L). D, Time to Half Relaxation (t1/2 off (s) L). L—length of cardiomyocytes;
sient rising half-time (t1/2 on (s) R). H, Calcium transient decay half-time (t1/2 off (s) R). R—F
(control: n=9; Ad.Val12, n=17; AdDNRas, n=11 cells); average of calcium transient parame
**P b 0.01.(Fig. 6, Table 1). Based on these results, we examined the effects of ras
mutants on adult cardiomyocyte contractility and Ca2+ handling in
the setting of POH. Ventricular myocytes were isolated from rats two
weeks after simultaneous aortic banding surgery and gene transfer;
subsequently, cardiomyocyte contractility and calcium transients were
evaluated as described in theMethods section. Fig. 7A shows recordings
from representative control ventricular myocytes (sham operated) and
POHmyocytes infected with either AdVal12 or AdDNRas. Interestingly,
AdVal12 overexpression induced signiﬁcant decreases in cell shortening
compared to AdDNRas (4.83 ± 0.71 %, n = 17 vs. 7.0 ± 0.66%, n = 11;setting of POH. A, Representative tracings of sarcomere shortening from control myocytes
d.DNRas in vivo. B, Sarcomere shortening, as a % of resting cell length. C, Time to Half Con-
E, representative Ca2+ transient tracings. F, Ca2+ transient, diastolic ratio. G, Calcium tran-
URA-2 340/380 ratio. Average parameters of cardiomyocyte contraction were determined
tersweredetermined (control: n=17; Ad.Val12, n=23;AdDNRas, n=13 cells) *P b 0.05,
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cating that contraction was accelerated in DNRas overexpressing
cardiomyocytes (t1/2 on(s)L = 0.05 ± 0.003 s for AdVal12, n = 17 vs.
0.04 ± 0.001 s for AdDNRas, n = 11; p b 0.05, Fig. 7C). Relaxation
half-time was unchanged between mutants (t1/2 off (s)L): 0.1 ±
0.015 s, n = 17 vs. 0.09 ± 0.014 s, n = 11; p = NS, Fig. 7D). These
adult myocyte mechanical abnormalities are consistent with what has
been observed in NRCM (Fig. 2) and alteration of ventricular function
in vivo (Fig. 6, Table 1).
To evaluate whether the observed effect of Val12 on myocytes con-
tractility is due to its effects on intracellular Ca2+ handling, cytoplasmic
Ca2+ transients were determined in FURA-2 loaded ventricular
myocytes. Ca2+ transients following POH and AdVal12 overexpression
were reduced (19.46 ± 1.45%, n = 17) compared to either control
(30.89 ± 3.19%, n = 17; p b 0.01) or AdDNRas-transduced myocytes
(22.96 ± 2.01%, n = 13; p b 0.01) (Fig. 7E and F). There was no effect
on the rising half-time of the calcium transient (Fig. 7G); however, the
half-time of calcium transient decay was accelerated only in the
DNRas group (Fig. 7H).
4. Discussion
4.1. Central role of Ras in physiologic and/or pathologic cardiomyocyte
hypertrophy
Pathologic cardiomyocyte hypertrophy is the result of a complex in-
teraction between signaling pathways leading to a manifold response
beyondmyocyte growth [5,31]. This interaction likely results in an equi-
librium, which is in turn displaced by the addition of Ras mutants, var-
iably affecting hypertrophy and some of its aspects. Cardiomyocyte
hypertrophy is not limited to an increase in cell size but is rather a mul-
tiform process involving transcriptional events, new protein synthesis,
and changes in the myoﬁlament organization [12,31].
Previous reports indeed suggest that Ras mutants have mixed ago-
nist and antagonist effects on cardiac hypertrophywhich aremodulated
by concurring hypertrophic stimuli: Gottshall et al. [7] mentioned
signiﬁant variability of phenotype among Ras-Val12 transgenic mice;
one explanation for this variability within and between studies may re-
side in the ﬁne balance on which the Ras system operates and the easy
displacement of the Ras equilibrium.
Here, we demonstrated a cardio-protective effect of DN-Ras beyond
its variable antihypertrophic effect using in vitro and in vivo gene trans-
fer studies. In vitro, DN-Ras maintains NRCM beating and enhances Z
line structure, is antihypertrophic onNRCMactivated by PE, and inhibits
NFAT. In vivo, DN-Ras decreased the expression levels of β-MHC and
ANF in hypertrophied hearts and reduced the cross-sectional area of
cardiac myocytes. Furthermore, DN-Ras enhances contractility and
ameliorates Ca2+ transient in cardiomyocytes in the setting of POH, in
comparison to the detrimental effects of Ras-Val12. In a previous
study, Ras-Val12 mutants impaired calcium transients in NRCM [9].
Taken together, our data show that the Ras signaling cascade can be
involved in physiological and/or pathological adaptations of cardiomyo-
cyte structure and function to altered haemodynamics, depending on
stimuli combination (Fig. 8). Physiological adaptation can be achieved
through modulation of the RAS/RAF/ERK signaling pathway; whereas
pathological remodeling requires the activation of the transcription fac-
tor NFAT [38,39]. Indeed, the expression of a constitutively active Ras
mutant induced transcriptional activation of NFAT, sarcomeric disorga-
nization and cardiac dysfunction.
Dominant negative Ras inhibits the agonist-induced transcriptional
activation of NFAT, but allows ERK phosphorylation under particular
conditions. Furthermore, the mixed agonist–antagonist effect of DN-
Ras is dependent on the concurring hypertrophic stimuli.
Our study of the effect of Rasmutants on cardiomyocyte hypertrophy
shows for the ﬁrst time that a known DN-Ras mutant (Ras N17) can
allow physiological hypertrophy to occur, while it is antihypertrophicunder classical ligand stimulation, favoring a mixed agonist–antagonist
response rather than a mere competitive antagonism. This evidence
highlights the difference within signaling pathways activated during
pathological and physiological remodeling. The mixed agonist and an-
tagonist actions of DN-Ras, as well as the agonist actions of active Val-
12 Ras are stimulus-dependent. This behavior suggests that Ras does
not have a simple switch on-off function but a highly complex role of
modulation, depending on the stimulus, as highlighted by the varied re-
sponses of cardiomyocytes to ras mutants in our experiments. Besides,
we studied thedifferential action of Rasmutants beyondmere hypertro-
phy, affecting sarcomeric organization in vitro, the pathologic character
of LV hypertrophy and ensuing LV and cardiomyocyte function in the
setting of POH in vivo.
4.2. Pathologic prohypertrophic effect of active Ras-Val12
4.2.1. Cardio-toxicity of Val12-Ras vitro
Here we have demonstrated that Ras-Val12 gene transfer to
NRCM caused sarcomeric disorganization and inhibited the beating of
cardiomyocytes, consistent with the ﬁnding of Ho et al.[9]. Unlike us,
Thorburn et al. [10] found that Ras-Val12 increased the organization of
sarcomeres similarly to PE. Differences in the promoter usedmay explain
the different results, since, in our study, Ras-Val-12 was overexpressed
through a CMV promoter, while in the study by Thorburn et al. Ras-
Val12 was overexpressed using its native Ras promoter [10].
We suggest that the cardio-toxicity of Val12-Ras could be related to
the involvement of active Ras in the transcriptional activation of the
pro-hypertrophic transcription factor NFAT. Indeed, as demonstrated
here, the expression of the constitutive active Rasmutant was sufﬁcient
to activate NFAT in the absence of other stimuli. In relation with this,
Ras-Val12 abolished NRCM beating within a few days after gene trans-
fer, whereas, DN-Ras maintained their beating for a longer time than
controls. This result, together with the enhancement of the sarcomeric
structure by DN-Ras, strongly suggests not only a pro-hypertrophic ef-
fect of Ras-Val12 but also a cardiotoxic one, while DN-Ras shows
cardio-protective properties despite a mixed-agonist–antagonist effect
on hypertrophy.
4.2.2. Effects of Val12-Ras in vivo in the setting of POH
Previously, Hunter J. et al. [17] have reported that Ras-Val12 induced
left ventricular hypertrophy with myocyte disarray and diastolic dys-
function in transgenic mice; however, echocardiography was not per-
formed in the latter study, therefore, LV geometry was not determined.
Another study by the same group [7] in echocardiography-selected
transgenicmice demonstrates concentric LV hypertrophywith increased
wall thickness, intraventricular obstruction and reduced fractional short-
ening in Ras-Val12mice. In contrast, our study of the added effect of Ras-
Val12 gene transfer on POH by ascending aortic banding demonstrates a
more eccentric hypertrophy associated with a signiﬁcant increase in LV
end-systolic diameter and a trend to reduce LV wall thickness along
with the previously demonstrated [7] reduced fractional shortening. In
addition, data from our study revealed that POH ventricular myocytes
transduced with Ras-Val12 exhibited depressed sarcomeric shortening
and depressed calcium transients compared to healthy cardiomyocytes
and POH cardiomyocytes overexpressing DN-Ras, conﬁrming the
cardiotoxic effect of Ras-Val12 in vivo.
4.3. DN-Ras as a mixed agonist–antagonist of cardiomyocyte hypertrophy
4.3.1. Comparison of DN-Ras N17 with other DN-Ras mutants
Our study shows that active and dominant-negative Ras mutants
differentially affect the different aspects of hypertrophy. Ras has been
shown to modulate NFAT activation in NRCM, with induction by Val-
12-Ras and inhibition of agonist-induced NFAT activation by N17-
DNRas [32]. In our experiments, Val-12 Ras activatedNFATwithout con-
curring stimulation, whereas DN-Ras had no effect on NFAT activity in
Fig. 8. Simpliﬁed schema showing the intracellular signaling pathways modulated by Ras in cardiomyocytes (adapted from Diana E. Jaalouk & Jan Lammerding, [45]). At the level of
cardiomyocytes, hemodynamic alterations and neurohormonal ligands can be sensed through a diverse group ofmembrane-anchoredmechanosensors including ion channels, cell-mem-
brane-spanning G-protein-coupled receptors, and growth-factor receptors. This mechanical sensing is then converted to biochemical signals by triggering the multi-step activation of
downstream partners in an array of signaling cascades in the cytoplasm. The highlights of such cascades include the threemodules of themitogen-activated protein kinase (MAPK) family
underscored by the activation of Ras, the PLC-related cascade leading to the alteration of Ca2+ signaling and PI3K signaling cascade required for the induction of hypertrophic remodeling.
The convergence of these pathways results in the activation of speciﬁc transcription factors including the nuclear factor of activated T cells (NFAT), involved in hypertrophic remodeling.
Singular activation of ERK signaling (through RAF or directly by GPCR) seems to support adaptive physiological remodeling. Ultimately, the net sumof gene-expression reprogramming in
cardiomyocytes dictates the structural and functional response of a cell to pressure overload.
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luciferase activity, conﬁrming previous observations [32].
The effects observed with dominant negatives Ras mutants depend
of the type of mutant. We used an N17 mutant employed also by
other studies [12,15,40] whereas several studies employed the Ala15-
Ras inhibitor [10,41]. The inhibitory action of DN-Ras-N17 is due to a re-
duced afﬁnity for GTP and a normal afﬁnity for GDP [18]. Interestingly, it
has been noted that Rasmutants with reduced afﬁnity for both GDP and
GTP did not inhibit growth [18], suggesting that Rasmutations affecting
GTP binding are more than a simple on-off switch and favoring our
mixed agonist–antagonist hypothesis, balanced by the molecular con-
text. Indeed, the actions of N17-DNRas are mediated by interaction
with Ras-guanine nucleotide exchange factors (Ras-GEF) [5].
4.3.2. Differential modulation of ERK and Raf by DN-Ras
The analysis of the classical Ras pathway showed that inNRCMstim-
ulated by AT-II, DN-Ras blocked Raf and ERKphosphorylation; butwhen
the NRCM were stimulated with PE, DN-Ras down-regulated Raf phos-
phorylation but did not block ERK phosphorylation, supporting a
stimulus-dependentmodulation of ERK by DNRas and PE. This observa-
tion is consistent with Lei et al. who found that PE activates ERK by
trans-activating EGFR and FGFR (Epidermal and Fibroblast Growth Fac-
tor Receptors) independent of the Ras/Raf/ERK pathway [42], and is also
consistent with the data from Duquesnes N et al. [15]. However these
data contrast with the study of Zou et al. [40]. There are clear methodo-
logical differences between the two studies. For example, in the study
by Zou et al. [40], pharmacologic inhibition of the farnesylation of Ras
was used, and N17-DNRas was expressed using plasmids with 3–5%
transfection efﬁciency, while our study used adenoviral vectors. More-
over, the study by Zou et al. [40] measured the phosphorylating activity
of ERK and Raf-1 rather than the phosphorylation measured by us. Our
data with AT-II and PE are of interest since they reveal a more potentactivation of ERK than of Raf-1, and the Ras-dependence of the activa-
tion of these targets by AT-II, but not by PE, for ERK. Thus, the blocking
effect of DN-Ras can be overridden by alternative signaling pathways.
This ﬁne regulation of DN-Ras that modulates ERK phosphorylation
under AT-II but not under PE is a very important observation illustrating
the mixed, apparently paradoxical, agonist–antagonist effect of DN-Ras
found in vitro and in vivo. On the other hand, active Ras-Val12 phos-
phorylated ERK strongly, but it increased phospho-Raf only slightly.
DN-Ras did not block ERK and Raf as consistently as expected. A likely
explanation is that the DN-Ras N17 mutant has a negative phenotype,
but it is not a negative null type mutant: DN-Ras decreases the afﬁnity
of Ras for GTP from 1 × 10−8 to 1 × 10−6.5 [18], maintaining a relatively
low but steady activation of Ras, permitted by the binding to GTP that
activates Ras.
4.3.3. Ras inhibition by siRNA-H-Ras as an alternative approach to
N17-DN-Ras
Considering that the results obtained with DN-Ras were mitigated
by the overexpression of a protein that was not a negative null mutant,
we complemented our experiments by the study of the effects of siRNA-
H-Ras transfection on NRCM. To our knowledge, this is the ﬁrst study to
use that approach. As shown in Fig. 4, siRNA-H-Ras inhibited PE-
induced NRCM hypertrophy and blunted the PE-induced expression of
hypertrophic markers as well as the PE-induced phosphorylation of
ERK1. Interestingly, siRNA-H-Ras reduced the baseline expression of
molecular markers of hypertrophy and the baseline phosphorylation
of ERK1 (Fig. 4C–F). Moreover, PE had a signiﬁcant stimulatory effect
on β-MHC and ANF expression despite the presence of siRNA-H-Ras
(Fig. 4C, D) along with the ability to induce the phosphorylation of
ERK1 (Fig. 4F) suggesting an additive effect of Ras-dependent and Ras-
independentmechanisms, especially for the agonist-induced phosphor-
ylation of ERK.
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Here, in contrastwith a previous study by Pracyk JB et al. [12],we have
demonstrated thatDN-Ras transduction preserved the sarcomeric organi-
zation and beating in cultured NRCM, suggesting a cardioprotective effect
of DN-Ras in vitro. In line with these ﬁndings on NRCM, adult ventricular
myocytes subjected to simultaneous POH and transduction with DN-Ras
exhibited sarcomere shortening similar to control and even accelerated
contraction. Calcium transients in DN-Ras transduced cardiomyocytes
did not differ signiﬁcantly fromcontrol transients,while calcium transient
decay was signiﬁcantly accelerated.
When superimposed on POH, DN-Ras did not affect LV geometry nor
did it inhibit LV hypertrophy; it indeed seemed to favor hypertrophy as
assessed by LV/bodyweight ratio (Fig. 6A, Table 1). In addition, we have
demonstrated that DN-Ras prevented the hypertrophic growth of
cardiomyocytes in vitro and the POH-induced increase in cardiomyo-
cyte cross-sectional area in vivo. There are a few possible explanations
to the contrast between the data on cardiomyocyte cross-sectional
area in vivo and LVweight/bodyweight. Bodyweights of rats at baseline
were similar between groups (Table 1). At two weeks after surgery,
body weight tended to be lower in DN-Ras than in saline or sham
groups, but was signiﬁcantly lower in Val-12 Ras, likely reﬂecting
blunted weight gain associated with adenoviral injection (Table 1).
Taken together, a trend to a higher LV weight for DN-Ras vs. saline
and a trend to a lower body weight could explain themarginal increase
in LV weight/body weight ratio for DN-Ras vs. saline (Fig. 6A, Table 1).
We attribute body weight differences to the attenuation of weight
gain by adenoviral infection.
Nonetheless, the analysis of the regulatory mechanisms of Ras
in vivo showed that DN-Ras suppressed the induction of β-MHC and
ANF by POH, while the latter remained increased with the transfection
of Val-12-Ras, although not exacerbated by it. This lack of in vivo anti-
hypertrophic effect of DN-Ras in POH can be explained mainly by the
presence of Ras-independent pathways. Fig. 8 summarizes the intracel-
lular signaling pathways modulated by Ras in cardiomyocytes. The Ras-
independent pathways were suggested by in vitro experiments by
Pracyk et al. [12] and others [40,42]. Pressure-overload induces the re-
lease of the prohypertrophic ligands endotheline, angiotensin and PE
[16]. These ligands are prohypertrophic through Ras-dependent and
Ras-independent pathways [14,41]. Besides, Duquesnes et al. have
shown that N17-DN-Ras plasmid transfection inhibited ERK activation
in NRCM at baseline but not under stretch [15]. Finally, our in vitro ex-
periments of ERK and Raf phosphorylation show that DN-Ras can
block ERK phosphorylation when the cardiac cells are stimulated by
AT-II but not by PE. These Ras-independent pathways, together with
the previously reported stimulus-dependent modulation of cardiomyo-
cyte hypertrophy by DNRas, provide explanations to the lack of
antihypertrophic effect of DN-Ras in the in vivo experiments involving
POH. In addition, and as mentioned earlier, parallel Ras-dependent
and Ras-independent mechanisms appear to be at work in the PE-
induced phosphorylation of ERK1 (Fig. 4F).4.4. Limitations
Our study suffers limitations of conceptual and methodological na-
ture. We used classical designs (NRCM, POH) to study a protein previ-
ously shown to affect cardiomyocyte hypertrophy; however, we went
on to evaluate the functional consequences of Rasmodulation in the set-
ting of hypertrophy. Measurable POH after 2 weeks is indeed observed
in this study and in previous studies [27,43]. Nevertheless, signiﬁcant
myocardial dysfunction following POH is best evaluated in longer stud-
ies, where signiﬁcant ventricular dilatation and transition to heart fail-
ure can be observed. Such a study would require the use of adeno-
associated virus for gene expression, while in the present study, we
used adenoviral vectors andwere limited by the 2weeks duration of ex-
pression these vectors allow in vivo [44].5. Conclusions
The present study is, to our knowledge, the ﬁrst one to study Ras
modulation in pressure-overload hypertrophy, and, in that setting, it
showed DN-Ras to be cardio-protective, although it was not anti-
hypertrophic. This lack of anti-hypertrophic effect can be explained by
mixed agonist–antagonist effects of DN-Ras that are stimulus-
dependent, and by the complexity of certain stimuli, such as pressure-
overload. Furthermore, this cardio-protective effect of DN-Ras has
some similarities with physiologic hypertrophy, especially the lower
expression level of β-MHC and ANF, along with the improved sarco-
mere shortening and calcium-handling patterns. It is consistent with
our ﬁnding of improved sarcomeric morphology and preserved
in vitro beating of neonatal cardiomyocytes. All these characteristics
of DN-Ras make Ras an interesting therapeutic target in pathological
cardiac hypertrophy.
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